2-(4-氨基苯氧基)乙基氨基甲酸叔丁酯 | 159184-15-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(4-氨基苯氧基)乙基氨基甲酸叔丁酯
• 英文名称: tert-butyl (2-(4-aminophenoxy)ethyl)carbamate
• 英文别名: 2-(4-Aminophenoxy)ethylcarbamic acid 1,1-dimethylethyl ester；tert-Butyl 2-(4-aminophenoxy)ethylcarbamate；tert-butyl N-[2-(4-aminophenoxy)ethyl]carbamate
• CAS: 159184-15-3
• 化学式: C₁₃H₂₀N₂O₃
• mdl: MFCD11922406
• 分子量: 252.313
• InChiKey: IBXPLCWUDLAXJC-UHFFFAOYSA-N

物化性质

• 沸点：
  421.7±25.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  73.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-(4-氨基苯氧基)乙基氨基甲酸叔丁酯 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 N-[3-[[3-[6-[4-[2-[[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetyl]amino]ethoxy]anilino]pyrimidin-4-yl]pyridin-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide
  参考文献：
  名称：

  Affinity Reagents that Target a Specific Inactive Form of Protein Kinases

  摘要：

  A number of small-molecule inhibitors have been developed that target the catalytic domains of protein kinases that are not in an active conformation. An inactive form that has been observed in several kinases is the DFG-out conformation. This conformation is characterized by an almost 180 degrees rotation of the conserved Asp-Phe-Gly (DFG) motif in the ATP-binding cleft relative to the active form. However, the sequence and structural determinants that allow a kinase to stably adopt the DFG-out conformation are not known. Here, we characterize a series of inhibitors based on a general pharmacophore for this inactive form. We demonstrate that modified versions of these inhibitors can be used to study the thermodynamics and kinetics of ligand binding to DFG-out-adopting kinases and for enriching these kinases from complex protein mixtures.

  DOI：

  10.1016/j.chembiol.2010.01.008
• 作为产物：
  描述：

  N-(叔丁氧羰基)乙醇胺 在 偶氮二甲酸二异丙酯 、 铁粉 、 氯化铵 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 7.0h， 生成 2-(4-氨基苯氧基)乙基氨基甲酸叔丁酯
  参考文献：
  名称：

  新型2,4,6-三取代喹唑啉衍生物作为潜在抗肿瘤药物的设计、合成和生物学评价

  摘要：

  在这项研究中，设计、合成了一系列新型2,4,6-三取代喹唑啉衍生物，并从生物学角度评估了它们对四种人类癌细胞系（Eca-109、A549、PC-3和MGC-803）的抗增殖活性。大多数设计的化合物对测试的四种癌细胞系表现出相当大的抗增殖活性，而化合物28g对MGC-803细胞和Eca-109细胞表现出最好的抗增殖活性，其IC 50值分别为1.95 μM和2.46 μM。进一步的机制研究表明，28g显着抑制MGC-803细胞的细胞迁移和集落形成。另外，28克还在 MGC-803 细胞中剂量依赖性地诱导细胞凋亡和细胞周期停滞在 S 期。总体而言，所有这些研究表明28g有潜力作为抗肿瘤药物开发的有价值的先导化合物。 图形概要

  DOI：

  10.1007/s00044-023-03114-x

文献信息

• CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130197205A1

  公开（公告）日：2013-08-01

  The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X 1 , X 4 , R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (α4β1) and alpha-V-beta-3 (αVβ3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.

  该发明涉及公式I的壳聚糖聚合物衍生物： 及其药用可接受的盐和酯，其中Y、X 1 、X 4 、R1、R2和n在详细说明和权利要求中有定义。公式I的壳聚糖聚合物衍生物与α4β1和αVβ3整合素二聚体结合或结合，并可用于传递制剂以将药物、核酸或其他治疗化合物传递到表达这些整合素的组织或细胞中。
• [EN] 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES DE 2-AMINO-4-HYDROXY-5-PYRIMIDINOCARBOXAMIDE ET COMPOSES ASSOCIES SERVANT D'INHIBITEURS DE L'ACTIVATION DES LYMPHOCYTES T POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：AMGEN INC

  公开号：WO2005009443A1

  公开（公告）日：2005-02-03

  The present invention relates to pyrimidine or pyridine carboxamides or pharmaceutically-acceptable salts thereof. Also included is a method of treatment of inflammation, inhibition of T cell activation and proliferation, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, organ transplant, acute transplant or heterograft or homograft rejection, transplantation tolerance induction, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleracielma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, atopic dermatitis, colon carcinoma or thymoma in a mammal comprising administering a therapeutically-effective amount a compound as described above.

  本发明涉及嘧啶或吡啶甲酰胺或其药用可接受的盐。还包括一种治疗炎症、抑制T细胞激活和增殖、关节炎、类风湿性关节炎、银屑病关节炎、骨关节炎、器官移植、急性移植或异体移植或同种异体移植排斥、移植耐受性诱导、缺血或再灌注损伤、心肌梗死、中风、多发性硬化症、炎症性肠病，包括溃疡性结肠炎、克罗恩病、狼疮、接触超敏反应、迟发型超敏反应和谷蛋白敏感性肠病、1型糖尿病、银屑病、接触性皮炎、桥本甲状腺炎、舍格伦综合征、自身免疫性甲状腺功能亢进、阿狄森病、自身免疫多腺体病、自身免疫性脱发、恶性贫血、白癜风、自身免疫性垂体功能减退、吉兰-巴雷综合征、肾小球肾炎、血清病、荨麻疹、过敏性疾病、哮喘、花粉症、过敏性鼻炎、硬皮病、真菌病、皮肌炎、斑秃、慢性日光性皮炎、湿疹、贝赫切特病、掌跖脓疱病、脓皮病、塞扎里综合征、特应性皮炎、系统性硬化病、硬皮病、特应性皮炎、结肠癌或胸腺瘤的方法，包括施用如上所述的化合物的治疗有效量。
• [EN] Phosphatase Binding Compounds and Methods of Using Same<br/>[FR] COMPOSÉS DE LIAISON À LA PHOSPHATASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV YALE

  公开号：WO2020146470A1

  公开（公告）日：2020-07-16

  The present invention provides bifunctional compounds that efficiently dephosphorylate certain phospho-activated target proteins. Such target proteins can be any protein involved in the pathway of a disease or disorder, such as but not limited to cancer, neurodegeneration, metabolic disease, diabetes, insulin resistance, and so forth.

  本发明提供了能够高效去磷酸化特定磷酸激活靶蛋白的双功能化合物。这些靶蛋白可以是与疾病或紊乱途径有关的任何蛋白质，比如但不限于癌症、神经退行性疾病、代谢性疾病、糖尿病、胰岛素抵抗等。
• Heterocyclic beta-3 adrenergic receptor agonists
  申请人：American Home Products Corporation

  公开号：US20020028832A1

  公开（公告）日：2002-03-07

  This invention provides compounds of Formula I having the structure 1 U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  这项发明提供了具有结构式I的化合物 1 其中U、V、W、X和Y如前文所定义， 或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐受有关）、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿；特别适用于治疗或抑制2型糖尿病。
• Substituted phenyl sulfonamides as selective .beta. 3 agonists for the
  申请人：Merck & Co., Inc.

  公开号：US05451677A1

  公开（公告）日：1995-09-19

  Substituted phenylsulfonamides are selective .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted alkyl epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.

  取代苯磺酰胺是选择性的β3肾上腺素受体激动剂，几乎没有β1和β2肾上腺素受体活性，因此这些化合物能够增加细胞内脂解和能量消耗。因此，这些化合物在治疗2型糖尿病和肥胖症方面具有强大的活性。这些化合物还可以用于降低甘油三酯水平和胆固醇水平，或提高高密度脂蛋白水平，或减少肠道蠕动。此外，这些化合物可以用于减少神经源性炎症或作为抗抑郁剂。这些化合物是通过将氨基烷基苯磺酰胺与适当取代的烷基环氧化合物偶联而制备的。还公开了这些化合物在治疗糖尿病和肥胖症以及降低甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或增加肠道蠕动方面的用途的组合物和方法。